On November 16, YaoTesco issued an announcement that Hao Ruizhi recently applied to resign as the secretary of the company's board of directors and deputy general manager due to personal reasons
.
Sinovac Pharmaceutical also announced on the evening of November 15 that Ms.
Shi Weijin applied to resign as the company's deputy general manager due to personal reasons, and will no longer hold any position
in the company after her resignation.
In the pharmaceutical industry, it is not uncommon for the deputy general manager of pharmaceutical companies to resign, and there have been many cases since October this year, and most of the reasons are mainly personal reasons
.
For example, in November, there was also a announcement by Cylon Pharmaceutical on November 2 that Mr.
Tong Yan applied to resign as the deputy general manager of the company due to personal reasons, and after his resignation, Mr.
Tong Yan will not hold any position in the company and its subsidiaries; On November 1, Thalys Medical announced that Mr.
Liu Feng, the company's deputy general manager, resigned as the company's deputy general manager due to personal reasons
.
IN OCTOBER, A LARGE NUMBER OF DEPUTY GENERAL MANAGERS OF PHARMACEUTICAL COMPANIES LEFT, INCLUDING LIU ZHAN FENG, DEPUTY GENERAL MANAGER IN CHARGE (PRODUCTION) OF DAFO PHARMACEUTICAL, MR.
SUN HAIFENG, MR.
XU PENG, DEPUTY GENERAL MANAGER OF FUAN PHARMACEUTICAL, MR.
MAOJIAN GU, DEPUTY GENERAL MANAGER OF SHANGHAI XUANTAI PHARMACEUTICAL, AND TAO WEIKANG, DEPUTY GENERAL MANAGER OF HENGRUI PHARMACEUTICAL, AMONG WHICH MR.
MAOJIAN GU, DEPUTY GENERAL MANAGER OF SHANGHAI XUANTAI PHARMACEUTICAL, LEFT DUE TO AGE, AND SEVERAL OTHER SENIOR EXECUTIVES WERE BASICALLY DUE TO PERSONAL REASONS
.
Of course, there are departures and new appointments
.
For example, Hengrui Pharmaceutical appointed He Feng as the deputy general manager of Hengrui Pharmaceutical on October 10, which will be responsible for the new drug research and development and R&D management of Shanghai Hengrui R&D center
.
It is reported that He Feng has worked at Bristol-Myers Squibb, Novartis and AbbVie, engaged in the research and development of innovative drugs in the fields of viruses, cancer, kidney disease and other diseases
.
On October 25, Luyan Pharmaceutical announced that upon nomination by the company's general manager, the company agreed to appoint Mr.
Wu Di as the company's deputy general manager
.
It is worth mentioning that the deputy general managers of many pharmaceutical companies have changed
many times.
For example, in addition to the resignation of Tao Weikang this year, on April 12, Zou Jianjun applied to resign as the company's deputy general manager for personal reasons, and on February 25, the company's deputy general manager Zhang Yuehong also applied for resignation
due to personal reasons.
In July 2017, Mr.
Zheng Chongbin, the company's deputy general manager, requested to resign as the company's deputy general manager due to retirement at an age, and on May 29, 2021, Mr.
Zhao Zhongming, deputy general manager of Luyan Pharmaceutical, resigned
due to personal reasons.
It is understood that the deputy general manager of the pharmaceutical company plays an important role in the process of enterprise development, as the general manager's staff and assistant, he needs to assist the general manager to formulate and implement the company's overall strategy and annual business plan, complete the responsibility objectives and annual plan, establish and improve the company's management system and organizational structure, etc
.
Behind the frequent changes in the deputy general managers of pharmaceutical companies, it can be seen that the transformation and adjustment of the pharmaceutical industry is accelerating
.
In recent years, with the normalization of centralized procurement, the development of consistency evaluation of generic drugs, and medical insurance fee control, pharmaceutical companies, especially traditional pharmaceutical companies, are generally under pressure, or face problems such as insufficient growth momentum and difficult transformation.
An industry insider Chen, "The transformation of traditional pharmaceutical companies in the current context is full of challenges, the tasks are heavy, and it is impossible to see the difference in the short term, and some pharmaceutical executives who are clear about the difficult prospects may have other choices
for their own way out.
" ”
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
